drugset / Trial / NCT00966251
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Phase 1/2
Terminated
2 enrolled
CureTech Ltd
Teva Branded Pharmaceutical Products R&D, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this pilot study is to evaluate the safety, tolerability and activity of the monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular Carcinoma.
Timeline
- Start
- 2009-10
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pidilizumab | Monoclonal antibody | — | Intravenous |